-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target

Benzinga·09/02/2026 10:32:49
语音播报
Morgan Stanley analyst Terence Flynn reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.